Selvita Reports Rebound in H2 2024 and 11% Increase in Backlog for 2025
KRAKOW, Poland, March 27, 2025 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of Europe's leading preclinical CROs, has announced its financial results for 2024 and provided an update on its backlog for 2025.
Key Highlights:
In Q4 2024, Selvita generated EUR 22.5 million in commercial revenues, marking a 14% year-over-year increase. EBITDA reached EUR 4.8 million, up 26% y/y1,2, with an EBITDA margin of 21.1%, compared to 14.1% in the first three quarters of the year. As anticipated, the second half of 2024 significantly outperformed the first, with commercial revenues up 20% and EBITDA increasing by 86% compared to H1.
Revenues from big pharma3 customers totaled EUR 20.2 million, a 51% y/y increase. Big Pharma now represents 26% of Selvita's revenue, reinforcing the Group's foundation with long-term contracts.
The backlog for 2025 stands at EUR 51 million4, reflecting an 11% y/y increase.
The company is optimistic about revenue growth from PozLab, acquired a year ago, and expects it to contribute positively to the Group's operating results by the end of 2025.
Selvita has ample capacity for organic growth, with secured infrastructure that, when fully utilized, could allow us to nearly double current revenue levels. Capital expenditure for 2025 is expected to be modest.
A video conference to discuss Selvita's 2024 results will be held on March 27 at 11:00 a.m. The event will be livestreamed at live.selvita.com.
Bogusław Sieczkowski, co-founder and Chief Executive Officer of Selvita, stated:
"As an organization, we remain highly flexible and continuously position ourselves for growth. Our strong H2 performance demonstrates our ability to swiftly capitalize on the improved sector financing environment, enabling us to restore EBITDA margins above 20%. We are entering 2025 with solid momentum, though recent weeks have seen a slowdown in customer decision-making. Our backlog suggests a stronger first half of the year compared to 2024, but maintaining momentum in H2 will depend on stabilization of volatile sentiment driven by macroeconomic uncertainty."
Dariusz Kurdas, Chief Financial Officer, added:
"The fourth quarter exceeded our expectations, contributing to nearly double the EBITDA level ...
